
FRLN
Healthcare · Biotechnology · $28.2M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2023
EPS trend, 90 days to now · +67.6% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Dec 29, 2023 | Before the open | -0.23 | -2.76 | -1099.0% |
| Aug 15, 2023 | Before the open | -3.14 | -4.16 | -32.5% |
| May 30, 2023 | Before the open | -3.10 | -4.36 | -40.6% |
| Mar 30, 2023 | Time not confirmed | -0.27 | -0.58 | -112.5% |
| Nov 15, 2022 | Before the open | -0.44 | -0.20 | +54.5% |
| Aug 9, 2022 | Before the open | -0.51 | -0.32 | +37.3% |
| May 10, 2022 | After the close | -0.60 | -0.63 | -5.0% |
| Mar 31, 2022 | After the close | -0.68 | -0.96 | -41.2% |
| Nov 9, 2021 | After the close | -1.01 | -0.86 | +14.9% |
| Aug 16, 2021 | Before the open | -0.97 | -1.12 | -15.5% |
| May 17, 2021 | After the close | -0.78 | -0.98 | -25.6% |
| Mar 31, 2021 | After the close | -0.72 | -0.88 | -22.2% |
| Oct 29, 2020 | After the close | -0.89 |
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and…
| -0.77 |
| +13.5% |
| Jun 3, 2020 | Time not confirmed | — | -13.65 | — |